Screener
Taysha Gene Therapies, Inc. TSHA Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -2,792.3%-1,631pp | -1,774.4%-549pp | -1,130.6%-33.1pp | -1,618.5%-733pp | -1,160.8%-554pp | |
| Net margin | -2,728%-1,583pp | -1,738.4%-537pp | -1,115.3%-43.6pp | -1,583.7%— | -1,145%— | |
| Returns | ||||||
| Return on equity | -47.1%+4.8pp | -97.3%+62.1pp | -68.5%+53.5pp | -64.9%— | -51.9%— | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×-0.1× | |
| Liquidity | ||||||
| Current ratio | 17.8×+5.3× | 14×+8.7× | 12.2×+6.8× | 10.5×+5.0× | 12.5×+7.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.1× | 0.3×-0.8× | 0.3×-0.6× | 0.3×-0.4× | 0.2×-0.3× | |
| Per Share | ||||||
| Book value per share | $1.05+25.7% | $0.58+183% | $0.77+170% | $0.62+87.0% | $0.83+78.5% | |
| Valuation | ||||||
| Market capitalization | $1.54B+16.0% | $1.28B+351% | $1.51B+325% | $892.04M+119% | $619.83M+36.5% | |
| Price / sales | 281.6×+70.6× | 171.9×+132× | 154.2×+112× | 141.4×+100× | 76.5×+41.3× | |
| Price / book | 4×-2.1× | 6.1×+0.9× | 6.1×+1.1× | 4.1×-0.5× | 2.5×-1.7× |
FAQ
- Where do Taysha Gene Therapies, Inc.'s ratios come from?
- Every ratio is computed from Taysha Gene Therapies, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
